Evidence map›Paper›PMID 32472768›Full record

Trial reportAIDS (London, England)2020

Population-level viral suppression among pregnant and postpartum women in a universal test and treat trial.

Jane Kabami, Laura B Balzer, Hachem Saddiki, James Ayieko, Dalsone Kwarisiima, Mucunguzi Atukunda, Edwin D Charlebois, Tamara D Clark, Catherine A Koss, Theodore Ruel and 7 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01864603 (Sustainable East Africa Research in Community Health), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Jane KabamiDepartment of Medicine, Makerere University College of Health Sciences.
Laura B BalzerUniversity of Massachusetts, Amherst, Massachusetts, USA.
Hachem SaddikiUniversity of Massachusetts, Amherst, Massachusetts, USA.
James AyiekoKenya Medical Research Institute, Nairobi, Kenya.
Dalsone KwarisiimaInfectious Diseases Research Collaboration, Kampala, Uganda.
Mucunguzi AtukundaInfectious Diseases Research Collaboration, Kampala, Uganda.
Edwin D CharleboisUniversity of California, San Francisco.
Tamara D ClarkUniversity of California, San Francisco.
Catherine A KossUniversity of California, San Francisco.
Theodore RuelUniversity of California, San Francisco.
Elizabeth A BukusiKenya Medical Research Institute, Nairobi, Kenya.
Craig R CohenUniversity of California, San Francisco.
Phillipa MusokeDepartment of Medicine, Makerere University College of Health Sciences.
Maya L PetersenUniversity of California, Berkeley, California, USA.
Diane V HavlirUniversity of California, San Francisco.
Moses R KamyaDepartment of Medicine, Makerere University College of Health Sciences.
Gabriel ChamieUniversity of California, San Francisco.
University of California, San Francisco · USMakerere University · UGInfectious Diseases Research Collaboration · UGKenya Medical Research Institute · KEUniversity of Massachusetts Amherst · USUniversity of California, Berkeley · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT · 1988 to 2026
$93.6M
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START)U01AI099959 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2016
$39.7M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Building Implementation Science Capacity at Makerere University to Strengthen the Response to the HIV/AIDS Epidemic in UgandaD43TW010037 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI KAMYA, MOSES ROBERT, SEMITALA, FRED C · 2015 to 2025
$3.3M
Optimizing Adherence to PrEP among Young African Women through a Community Adherence Club InterventionK23MH114760 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOSS, CATHERINE ANNE STIMETS · 2018 to 2021
$796k
FIC NIH HHS D43 TW010037NIAID NIH HHS P30 AI027763NIAID NIH HHS U01 AI099959NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069496NIMH NIH HHS K23 MH114760
6 · The paper itself

Abstract

OBJECTIVE(S): We sought to determine whether universal 'test and treat' (UTT) can achieve gains in viral suppression beyond universal antiretroviral treatment (ART) eligibility during pregnancy and postpartum, among women living with HIV.

designA community cluster randomized trial.

methodsThe SEARCH UTT trial compared an intervention of annual population testing and universal ART with a control of baseline population testing with ART by country standard, including ART eligibility for all pregnant/postpartum women, in 32 communities in Kenya and Uganda. When testing, women were asked about current pregnancy and live births over the prior year and, if HIV-infected, had their viral load measured. Between arms, we compared population-level viral suppression (HIV RNA <500 copies/ml) among all pregnant/postpartum HIV-infected women at study close (year 3). We also compared year-3 population-level viral suppression and predictors of viral suppression among all 15 to 45-year-old women by arm.

resultsAt baseline, 92 and 93% of 15 to 45-year-old women tested for HIV: HIV prevalence was 12.6 and 12.3%, in intervention and control communities, respectively. Among HIV-infected women self-reporting pregnancy/live birth, prevalence of viral suppression was 42 and 44% at baseline, and 81 and 76% (P = 0.02) at year 3, respectively. Among all 15 to 45-year-old HIV-infected women, year-3 population-level viral suppression was higher in intervention (77%) versus control (68%; P < 0.001). Pregnancy/live birth was a predictor of year-3 viral suppression in control (P = 0.016) but not intervention (P = 0.43). Younger age was a risk factor for nonsuppression in both arms.

conclusionThe SEARCH intervention resulted in higher population viral suppression among pregnant/postpartum women than a control of baseline universal testing with ART eligibility for pregnant/postpartum women.

Indexed as

AdolescentAdultAnti-HIV AgentsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveFemaleHIV InfectionsHumansKenyaMiddle AgedPostpartum PeriodPregnancyPregnant PeoplePrevalenceUgandaViral LoadAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

PMID32472768
PMCPMC7360881
OpenAlexW3029057267

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.